The aging of the 2000 and 2011 Hallmarks of Cancer reviews: A critique

Journal of Biosciences

Volumn 38, Issue 3, 2013, Pages 651-663

  Sonnenschein, Carlos ^a   Soto, Ana M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Oncogenes; proliferation; somatic mutation theory; stroma; tissue organization field theory

Indexed keywords

EPIDERMAL GROWTH FACTOR; NERVE GROWTH FACTOR; PROTEIN P107; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AGING; CANCER; CARCINOGEN; DNA; MUTATION;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; DNA SEQUENCE; ENERGY METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; SOMATIC MUTATION; TUMOR ESCAPE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

AGING; CARCINOGENESIS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PEER REVIEW, RESEARCH;

EID: 84883205105     PISSN: 02505991     EISSN: 09737138     Source Type: Journal    
DOI: 10.1007/s12038-013-9335-6     Document Type: Article

References (81)

1. Agathocleous M, Love NK, Randlett O, Harris JJ, Liu J, Murray AJ and Harris WA 2012 Metabolic differentiation in the embryonic retina. Nat. Cell Biol. 14:859-864
2. Alberts B 2010 Model organisms and human health. Science 330 1724
3. Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P 2008 Molecular biology of the cell (London: Garland Science)
4. Ayala FJ 1968 Biology as an autonomous science. Am. Sci. 56 207-221
5. Baker SG 2012 Paradoxes in carcinogenesis should spur new avenues of research: An historical perspective. Disruptive Sci. Technol. 1 100-107
6. Baker SG 2013 Paradox-driven cancer research. Disruptive Sci. Technol. 1 143-148
7. Baserga R 1976 Multiplication and division of mammalian cells (New York, NY: M Dekker)
8. Bertolaso M 2011 Hierarchies and causal relationships in interpretative models of the neoplastic process. Hist. Phil. Life Sci. 33 515-535
9. Bishop JM 1991 Molecular themes in oncogenesis. Cell 64 235-248
10. Bizzarri M, Cucina A, Conti F and D'Anselmi F 2008 Beyond the oncogene paradigm: understanding complexity in cancerogenesis. Acta Biotheor. 56 173-196
11. Booth BW, Boulanger CA, Anderson LH and Smith GH 2011 The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells. Oncogene 30 679-689
12. Brumfiel G 2012 Theorists feast on Higgs data. Nature 487 281
13. Bussard KM, Boulanger CA, Booth BW, Bruno RD and Smith GH 2010 Reprogramming human cancer cells in the mouse mammary gland. Cancer Res. 70 6336-6343
14. Cardiff RD, Ward JM and Barthold SW 2008 'One medicine - one pathology': are veterinary and human pathology prepared? Lab Invest. 88 18-26
15. Cohen S 1965 Growth factors and morphogenic induction; in Developmental and metabolic control mechanisms and neoplasia (Baltimore, MD: Williams and Wilkins) pp 251-272
16. Cohen S and Elliot GA 1962 The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse. J. Invest. Dermat. 49 1-5
17. Cooper GM 1997 The cell: A molecular approach (Washington: ASM Press)
18. Drach JC, Thomas MA, Barnett JW, Smith SH and Shipman C Jr 1981 Tritiated thymidine incorporation does not measure DNA synthesis in ribavirin-treated human cells. Science 212 549-551
19. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D and Jain RK 2010 Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 107 21677-21682
20. Dunn GP, Old LJ and Schreiber RD 2004 The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 329-360
21. Durum SK and Muegge K 1998 Cytokine knockouts (Totowa: Humana Press)
22. Ebos JM and Kerbel RS 2011 Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8 210-221
23. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC and Weinberg RA 2001 Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 50-65
24. Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L and Hahnfeldt P 2009 Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res. 69 881-821
25. Enderling H and Hahnfeldt P 2011 Cancer stem cells in solid tumors: Is 'evading apoptosis' a hallmark of cancer? Prog. Biophys. Mol. Biol. 106 391-399
26. Fuchs EJ and Matzinger P 1996 Is cancer dangerous to the immune system? Semin. Immunol. 8 271-280
27. Garraway LV and Lander EC 2013 Lessons from the cancer genome. Cell 153 17-37
28. Gilbert SF 2010 Developmental biology (Sunderland: Sinauer Associates, Inc)
29. Hanahan D and Weinberg RA 2000 The hallmarks of cancer. Cell 100 57-70
30. Hanahan D and Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674
31. Harris H 2004 Tumor suppression: putting on the breaks. Nature 427 201
32. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM and Postovit LM 2007 Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7 246-255
33. Illmensee K and Mintz B 1976 Totipotency and normal differentiation of single teratocarcinoma cell cloned by injection into blastocysts. Proc. Nat. Acad. Sci. USA 73 549-553
34. Institute of Medicine 2013 Delivering affordable cancer care in the 21st century:Workshop summary (Washington DC: The National Academies Press)
35. Interagency Breast Cancer & Environmental Research Coordinating Committee. 2013 Breast cancer and the environment: Prioritizing prevention (http://www.niehs.nih.gov/about/assets/docs/ibcercc-full.pdf)
36. Jacobsen K, Groth A and Willumsen B 2002 Ras inducible immortalized fibroblasts: focus formation without cell cycle deregulation. Oncogene 21 3058-3067
37. Kaiser J 2012 Profile: Bert Vogelstein. Cancer genetics with an edge. Science 337 282-284
38. Laconi E 2007 The evolving concept of tumor microenvironments. BioEssays 29 738-744
39. Lazebnik Y 2010 What are the hallmarks of cancer? Nat. Rev. Cancer 10 232-233
40. Levi-Montalcini R 1986 The nerve growth factor: thirty-five years later. The Nobel Lectures 279-299
41. Levine AJ 2011 Introduction: The changing directions of p53 research. Genes Cancer 2 382-384
42. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D and Darnell J 2000 Overview of the cell cylce and its control; in Molecular cell biology (New York: W.H.Freeman)
43. Longo G, Miquel P-A, Sonnenschein C and Soto AM 2012 Is information a proper observable for biological organization? Prog. Biophys. Mol. Biol. 109 108-14
44. Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, et al. 2002 Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21 4577-4586
45. Luria SE 1975 Lecture 1; in 36 Lectures in biology (Cambridge: MIT Press) pp 3-14
46. Maffini MV, Calabro JM, Soto AM and Sonnenschein C 2005 Stromal regulation of neoplastic development: Age-dependent normalization of neoplastic mammary cells by mammary stroma. Am. J. Pathol. 167 1405-1410
47. Maffini MV, Soto AM, Calabro JM, Ucci AA and Sonnenschein C 2004 The stroma as a crucial target in rat mammary gland carcinogenesis. J. Cell Sci. 117 1495-1502
48. Marcum JA 2005 Metaphysical presuppositions and scientific practices: Reductionism and organicism in cancer research. Int. Stud. Philos. Sci. 19 31-45
49. Miklos GLG 2005 The human cancer genome project - one more mistep in the war on cancer. Nat. Biotechnol. 23 535-537
50. Mintz B and Ilmensee K 1975 Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Nat. Acad. Sci. USA 72 3585-3589
51. Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, Tsherniak A, Besche HC, et al. 2012 Cancer vulnerabilities unveiled by genomic loss. Cell 150 842-854
52. Pitot HC 2002 Fundamentals of oncology (New York: Marcel Decker)
53. Podlaha O, Riester M, De S and Michor F 2012 Evolution of the cancer genome. Trends Genet. 28 155-163
54. Rather LJ 1978 The genesis of cancer (Baltimore: Johns Hopkins University Press)
55. Rubin H 2011a Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. BioEssays 33 224-231
56. Rubin H 2011b The early history of tumor virology: Rous, RIF, and RAV. Proc. Nat. Acad. Sci. USA 108 14389-14396
57. Scully JL and Edwards PA 1991 Transformation of a mammary epithelial cell line by the v-raf and v-mos oncogenes. Int. J. Cancer 48 128-135
58. Senturk E and Manfredi JJ 2012 Mdm2 and tumorigenesis: evolving theories and unsolved mysteries. Genes Cancer 3 192-198
59. Sharov AA, Weiner L, Sharova TY, Siebenhaar F, Atoyan R, Reginato AM, McNamara CA, Funa K, et al. 2003 Noggin overexpression inhibits eyelid opening by altering epidermal apoptosis and differentiation. EMBO J. 22 2992-3003
60. Sonnenschein C and Soto AM 1980 But. are estrogens per se growth-promoting hormones?. J. Nat. Cancer Inst. 64 211-215
61. Sonnenschein C and Soto AM 1999 The society of cells: Cancer and control of cell proliferation (New York: Springer Verlag)
62. Sonnenschein C and Soto AM 2000 The somatic mutation theory of carcinogenesis: Why it should be dropped and replaced. Mol. Carcinog. 29 1-7
63. Sonnenschein C and Soto AM 2008 Theories of carcinogenesis: an emerging perspective. Semin. Cancer Biol. 18 372-377
64. Sonnenschein C and Soto AM 2011 The death of the cancer cell. Cancer Res. 71 4334-4337
65. Soto AM and Sonnenschein C 1987 Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocr. Rev. 8 44-52
66. Soto AM and Sonnenschein C 2004 The somatic mutation theory of cancer: growing problems with the paradigm? BioEssays 26 1097-1107
67. Soto AM and Sonnenschein C 2011 The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory. BioEssays 33 332-340
68. Soto AM and Sonnenschein C 2012 Is systems biology a promising approach to resolve controversies in cancer research? Cancer Cell Int. 12 12
69. Soto AM, Sonnenschein C and Miquel P-A 2008 On physicalism and Downward Causation in Developmental and Cancer Biology. Acta Biotheoretica 56 257-274
70. Stutman O 1974 Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183 534-536
71. Tallbot SL 2013 The myth of the machine-organism from genetic mechanisms to living beings; in Genetic explanations, sense and nonsense (eds) S Krimsky and J Gruber (Cambridge, MA: Harvard University Press) pp 51-68
72. Tarin D 2011 Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Semin. Cancer Biol. 21 72-82
73. Tarin D, Thompson EW and Newgreen DF 2005 The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65 5996-6000
74. Varmus H and Kumar HS 2013 Addressing the growing international challenge of cancer: a multinational perspective. Sci. Transl. Med. doi: 10.1126/scitranslmed.3005899
75. Visvader JE 2011 Cells of origin in cancer. Nature 469 314-322
76. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW 2013 Cancer genome landscapes. Science 339 1546-1558
77. Weinberg RA 1998 One renegade cell: how cancer begins (New York: Basic Books)
78. Weinberg RA 2006 The Biology of Cancer (New York: Taylor & Francis)
79. Wolff S and Bodycote J 1986 Metabolic breakdown of [3H] thymidine and the inability to measure human lymphocyte proliferation by incorporation of radioactivity. Proc. Nat. Acad. Sci. USA 83 4749-4753
80. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P and Smith A 2008 The ground state of embryonic stem cell self-renewal. Nature 453 519-523
81. Yusuf I and Fruman DA 2003 Regulation of quiescence in lymphocytes. Trends in Immunology 24 380-386